Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
23
12
2022
Statut:
ppublish
Résumé
To describe the dynamics of neutralizing antibody (NAbs) response after yellow fever (YF) vaccine in young adults and adolescents with perinatally acquired HIV (pHIV). A retrospective cross-sectional study at three time points around YF vaccination and a matched case-control comparison of NAbs titers several years after YF vaccination. We selected patients who had both documented YF vaccination and perinatally acquired HIV (n = 46). The NAbs titers were measured in plasma samples from the following three time points: during the two years before (TP0), within the year after (TP1) and >1 year after (TP2) administration of the YF vaccine. The impact of perinatal infection was assessed by comparing pHIV YF vaccinees with 44 controls infected with HIV during adulthood. The median time between the YF vaccine and TP1 and TP2 was 123 days and 7.3 years, respectively. After YF vaccination, 85% of vaccinees experienced seroconversion. The proportion of pHIV patients with NAbs above the protective threshold was stable between TP1 and TP2 (91% and 86%, respectively) but levels of NAbs decreased significantly between TP1 and TP2 (P = 0.0122). The case-control analysis found slightly higher geometrical mean titers (GMT) in pHIV than patients infected during adulthood. Patients with pHIV showed high seroconversion rate and NAbs persistence at levels above the protective threshold after first YF vaccination. However, a decline in antibody levels over time suggests that at least one revaccination may be necessary to maintain circulating antibodies, contrary to recommendations for the general population.
Identifiants
pubmed: 36541645
doi: 10.1097/QAD.0000000000003433
pii: 00002030-202302010-00014
doi:
Substances chimiques
Antibodies, Neutralizing
0
Yellow Fever Vaccine
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-346Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ali Judd, et al. , for the Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord. EuroCoord Work Group for the K to AWG and DM and HG in. Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. Eurosurveillance. 2016;21:30162.
Menson E, Mellado M, Bamford A, Castelli G, Duiculescu D, Marczyńska M, et al. Guidance on vaccination of HIV-infected children in Europe . HIV Med 2012; 13:333–336.
The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, Slogrove AL, Schomaker M, Davies MA, Williams P, Balkan S, et al. The epidemiology of adolescents living with perinatally acquired HIV: a cross-region global cohort analysis. PLoS Med. 2018;15:e1002514.
Beun AJ, Grammens T, Hainaut M, Barlow P, Van den Wijngaert S, Delforge M, et al. High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: a case-control study . Vaccine 2019; 37:5930–5933.
Dauby N. Perinatal HIV and response to vaccination . AIDS Lond Engl 2019; 33:1674–1675.
Abzug MJ, Qin M, Levin MJ, Fenton T, Beeler JA, Bellini WJ, et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy . J Infect Dis 2012; 206:512–522.
Dauby N, Martin C, Hainaut M, Grammens T, Van den Wijngaert S, Delforge M, et al. Prevalence and risk factors of measles seronegativity in a cohort of HIV-positive subjects: a retrospective study . HIV Med 2018; 19:426–429.
Sutcliffe CG, Moss WJ. Do children infected with HIV receiving HAART need to be revaccinated? . Lancet Infect Dis 2010; 10:630–642.
Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis . Clin Infect Dis 2014; 58:1130–1139.
Mutsaerts EAML, Nunes MC, van Rijswijk MN, Klipstein-Grobusch K, Grobbee DE, Madhi SA. Safety and immunogenicity of measles vaccination in HIV-infected and HIV-exposed uninfected children: a systematic review and meta-analysis . E Clin Med 2018; 1:28–42.
Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children . Proc Natl Acad Sci USA 2009; 106:7939–7944.
Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection . Pediatrics 2006; 118:e315–e322.
Flynn PM, Abrams EJ. Growing up with perinatal HIV . AIDS Lond Engl 2019; 33:597–603.
Rodríguez-Morales AJ, Bonilla-Aldana DK, Suárez JA, Franco-Paredes C, Forero-Peña DA, Mattar S, et al. Yellow fever reemergence in Venezuela – implications for international travelers and Latin American countries during the COVID-19 pandemic . Travel Med Infect Dis 2021; 44:102192.
Pistone T, Ouattara E, Gabillard D, Lele N, Duvignaud A, Cordel H, et al. Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: the ANRS VIHVO cohort study . Travel Med Infect Dis 2019; 29:40–47.
UNAIDS_FactSheet_en.pdf. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf .
Teasdale CA, Zimba R, Abrams EJ, Sachathep K, Ndagije F, Nuwagaba-Biribonwoha H, et al. Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cross-sectional population-based HIV impact assessment surveys . Lancet HIV 2022; 9:e91–e101.
Martin C, Domingo C, Bottieau E, Buonfrate D, De Wit S, Van Laethem Y, et al. Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: a systematic review . Clin Microbiol Inf 2021; 27:958–967.
Sibailly TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, et al. poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1 . Pediatr Infect Dis J 1997; 16:1177–1179.
Kling K, Domingo C, Bogdan C, Duffy S, Harder T, Howick J, et al. Duration of protection after vaccination against yellow fever – systematic review and meta-analysis . Clin Infect Dis 2022; 20:ciac580.
Obaro S, Pugatch D, Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children . Lancet Infect Dis 2004; 4:510–518.
Veit O, Domingo C, Niedrig M, Staehelin C, Sonderegger B, Héquet D, et al. Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV rna suppression status: implications for vaccination schedule . Clin Infect Dis 2018; 66:1099–1108.
Martin C, Florence E, Domingo C, Delforge M, De Wit S, Dauby N. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity . J Travel Med 2022; 14:taac024.
Ruggiero A, Pascucci GR, Cotugno N, Domínguez-Rodríguez S, Rinaldi S, Tagarro A, et al. Determinants of B-cell compartment hyperactivation in European adolescents living with perinatally acquired HIV-1 after over 10 years of suppressive therapy . Front Immunol 2022; 13:860418.
WHO. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations . Vaccine 2015; 33:76–77.
Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients . Clin Infect Dis 2009; 48:659–666.
Barte H, Horvath TH, Rutherford GW. Yellow fever vaccine for patients with HIV infection . Cochrane Database Syst Rev 2014; 1:CD010929.
Muyanja E, Ssemaganda A, Ngauv P, Cubas R, Perrin H, Srinivasan D, et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine . J Clin Invest 2014; 124:3147–3158.